Effects of Pygeum africanum extract (Tadenan®) on vasoactive intestinal peptide receptors, G proteins, and adenylyl cyclase in rat ventral prostate

Prostate

Volumn 45, Issue 3, 2000, Pages 245-252

  Solano, Rosa M ^a   Olga Garca Fernndez, M ^a   Clemente, Celia ^a   Querol, Manuel ^b   Bellamy, Franois ^c   Sanchez Chapado, Manuel ^a,d   Prieto, Juan C ^a   Carmena, Mara J ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

^b Laboratorios Fournier   (Spain)

^c Laboratoires Debat   (France)

^d HOSPITAL UNIVERSITARIO PRÍNCIPE DE ASTURIAS   (Spain)

Author keywords

G proteins; Phytotherapy; VIP

Indexed keywords

ADENYLATE CYCLASE; FORSKOLIN; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN SUBUNIT; PYGEUM AFRICANUM EXTRACT; TESTOSTERONE; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CASTRATION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVATION; MALE; NONHUMAN; PHYTOTHERAPY; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PROSTATE VENTRAL LOBE; RAT; SIGNAL TRANSDUCTION;

ADENYLATE CYCLASE; ADMINISTRATION, ORAL; ANIMALS; CELL DIVISION; FATTY ALCOHOLS; GROWTH INHIBITORS; GTP-BINDING PROTEINS; MALE; PROSTATE; RATS; RATS, WISTAR; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE;

EID: 0033765024     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0045(20001101)45:3<245::AID-PROS7>3.0.CO;2-T     Document Type: Article

References (43)

1. Economic modeling to assess the cost of treatment with finasteride, terazosin, and transurethral resection of the prostate for men with moderate to severe symptoms of benign prostatic hyperplasia
2. Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients
3. Phytotherapy for the prostate
4. Phytotherapy in treatment of benign prostatic hyperplasia: A critical review
5. Cactus flower extracts may prove beneficial in benign prostatic hyperplasia due to inhibition of 5 alpha reductase activity, aromatase activity and lipid peroxidation
6. 1-adrenoceptors in vitro
7. A multicentric, placebo-controlled, double-blind clinical trial of β-sitosterol (phytosterol) for the treatment of benign prostatic hyperplasia
8. Review of recent placebo-controlled trials utilizing phytotherapeutic agents for treatment of BPH
9. Other medical therapies
10. Efficacy of Pygeum africanum extract in the treatment of micturitional disorders due to benign prostatic hyperplasia. Evaluation of objective and subjective parameters
11. Comparison of once and twice daily dosage forms of Pygeum africanum extract in patients with benign prostatic hyperplasia: A randomized, double-blind study, with long-term open label extension
12. Comparison of finasteride (Proscar), a 5 alpha reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5 alpha reductase inhibition
13. Protective effect of Tadenan on bladder function secondary to partial outlet obstruction
14. Anti-inflammatory action of Pygeum africanum extract in the rat
15. Effect of Pygeum africanum extract on A23187-stimulated production of lipoxygenase metabolites from human polymorphonuclear cells
16. Antiproliferative effect of Pygeum africanum extract on rat prostatic fibroblasts
17. Apoptosis and benign prostatic hypertrophy
18. Clinical oncology update: Prostate cancer. Androgens and prostate cancer: Biology, pathology and hormonal therapy
19. Stimulation of androgen-regulated transactivation by modulators of protein phosphorylation
20. Differential sensitivity of human prostatic cancer cell lines to the effects of protein kinase and phosphatase inhibitors
21. Activation of the human androgen receptor through a protein kinase A signalling pathway
22. Synergistic activation of androgen receptor by androgen and luteinizing hormone-releasing hormone in prostate carcinoma cells
23. 2+ transients
24. Cyclic AMP signalling and cellular proliferation: Regulation of CREB and CREM
25. Characterization of vasoactive intestinal peptide/pituitary adenylate cyclase-activating peptide receptors in human benign hyperplastic prostate
26. Receptors for vasoactive intestinal peptide on isolated epithelial cells of rat ventral prostate
27. Cyclic AMP-stimulating effect of vasoactive intestinal peptide in isolated epithelial cells of rat ventral prostate
28. Hormonal control of apoptosis: The rat prostate gland as a model system
29. The effect of streptozotocin diabetes on the vasoactive intestinal peptide receptor/effector system in membranes from rat ventral prostate
30. A rapid and sensitive method for the quantification of microgram quantities of protein utilizing the principle of protein binding
31. A protein binding assay for adenosine 3':5'cyclic monophosphate
32. LIGAND: A versatile computerized approach for characterization of ligand-binding systems
33. Evaluation of inhibitory guanine nucleotide regulatory protein Gi function in hepatocyte and liver membranes from obese Zucker (fa/fa) rats and their lean (fa?) littermates
34. Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer
35. Activation of programmed cell death in the rat ventral prostate after castration
36. Influence of castration and testosterone treatment on the vasoactive intestinal peptide receptor/effector system in rat prostatic epithelial cells
37. Peptidergic innervation of the human prostate, seminal vesicle and vas deferens
38. Differential effects of peptide hormones bombesin, vasoactive intestinal polypeptide and somatostatin analog RC-160 on the invasive capacity of human prostatic carcinoma cells
39. Differential effects of arachidonic acid on the vasoactive intestinal peptide receptor/effector system in rat prostatic epithelium during sexual maturation
40. Diabetes-induced alterations in the expression, functioning and phosphorylation state of the inhibitory guanine nucleotide regulatory protein Gi-2 in hepatocytes
41. Genes regulated by androgen in the rat ventral prostate
42. Apoptosis during castration-induced regression of the prostate is Fos dependent
43. Regulation of cellular calcium through signalling cross-talk involves an intricate interplay between the actions of receptors, G-proteins, and second messengers